- Oxygen Closes $17 Million Series A Funding Round to Build the Banking Platform for the 21st Century Economy
- Nuverra Extends Maturity of First and Second Lien Credit Facilities
- CIT Serves as Agent on $185 Million Credit Facility for Orscheln Farm and Home
- Briggs & Stratton Corporation Announces New Revolving Credit Facility
- California Resources Corporation Completes Financial Restructuring
Kane Biotech Enters into Credit Facility with Pivot Financial
November 9, 2020
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (“Kane Biotech”) today announced that it has entered into a one year credit agreement (the “Credit Agreement”) with Pivot Financial Inc. (“Pivot”) for a non-revolving term loan in the aggregate amount of $1,480,000.00 (the “Credit Facility”).
In connection with the Credit Facility, Kane Biotech has entered into a general security agreement in favour of Pivot on terms and conditions customary in such transactions. The Credit Facility shall be used by Kane Biotech for: (i) funding research and development relating to eligible government reimbursable expenditures; (ii) expenses related to STEM Animal Health Inc; and (iii) general working capital purposes.
“This non-dilutive credit facility has been secured at an opportune time for Kane Biotech as it enters manufacturing, animal study and human study phases of its DispersinB® wound care program in the coming months. These phases of work will require significant cash outlays prior to funding being subsequently received from existing Western Economic Diversification Canada Business Scale-Up and Productivity and U.S. Department of Defense Medical Technology Enterprise Consortium Research Project Award funding programs,” stated Ray Dupuis, Chief Financial Officer of Kane Biotech.
Dan Flaro, President of Pivot added, “We’re pleased to welcome Kane to our family of clients and look forward to working with the management team as they continue to commercialize their impressive “made in Canada” portfolio of intellectual property.”
About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. Kane Biotech has a portfolio of biotechnologies, intellectual property (52 patents and patents pending, trade secrets and trademarks) and products developed by Kane Biotech's own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex®, bluestem™, silkstem™, coactiv+™ and Kane® are trademarks of Kane Biotech Inc. Kane Biotech is listed on the TSX Venture Exchange under the symbol "KNE” and on OTCQB Markets under the symbol “KNBIF". For more information, please visit www.kanebiotech.com, or contact:
Chief Executive Officer, Kane Biotech Inc.
Chief Financial Officer, Kane Biotech Inc.
+1 (514) 910-6991
+1 (204) 298-2200
+1 (416) 842-9003
In This Section